ADRB3 and obesity due to melanocortin 4 receptor deficiency: The use of β3-AR agonists as potential therapeutics for obesity and type-2 diabetes has been pursued intensively in the recent past, but lack of efficacy or side effects (mainly due to adrenergic stimulation of the cardiovascular system) have prevented translation to clinical application46.